Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Aurinia Pharmaceuticals Inc’s stock clocked out at $8.00, down -1.72% from its previous closing price of $8.14. In other words, the price has decreased by -$1.72 from its previous closing price. On the day, 0.96 million shares were traded. AUPH stock price reached its highest trading level at $8.17 during the session, while it also had its lowest trading level at $7.92.
Ratios:
To gain a deeper understanding of AUPH’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 39.83. For the most recent quarter (mrq), Quick Ratio is recorded 5.11 and its Current Ratio is at 5.60. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.19.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 09 ’24 when TANG KEVIN bought 500,000 shares for $9.09 per share. The transaction valued at 4,545,000 led to the insider holds 8,429,500 shares of the business.
TANG KEVIN bought 400,000 shares of AUPH for $3,604,000 on Dec 06 ’24. The Director now owns 7,929,500 shares after completing the transaction at $9.01 per share. On Dec 05 ’24, another insider, TANG KEVIN, who serves as the Director of the company, bought 300,000 shares for $8.91 each. As a result, the insider paid 2,673,000 and bolstered with 7,529,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1145432064 and an Enterprise Value of 885050176. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.20 while its Price-to-Book (P/B) ratio in mrq is 2.95. Its current Enterprise Value per Revenue stands at 4.016 whereas that against EBITDA is 1787.98.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.23, which has changed by 0.059895873 over the last 52 weeks, in comparison to a change of 0.21794415 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $10.67, while it has fallen to a 52-week low of $4.71. The 50-Day Moving Average of the stock is -7.57%, while the 200-Day Moving Average is calculated to be 18.24%.
Shares Statistics:
It appears that AUPH traded 1.45M shares on average per day over the past three months and 1138870 shares per day over the past ten days. A total of 143.11M shares are outstanding, with a floating share count of 128.78M. Insiders hold about 10.06% of the company’s shares, while institutions hold 39.47% stake in the company. Shares short for AUPH as of 1736899200 were 7476649 with a Short Ratio of 5.16, compared to 1734048000 on 5529334. Therefore, it implies a Short% of Shares Outstanding of 7476649 and a Short% of Float of 5.25.
